Pharmaceutical Technology

NOVEMBER 11, 2022

The European Commission (EC) has granted approval for Sanofi and GSK ’s monovalent, recombinant-protein-based, adjuvanted Covid-19 vaccine, VidPrevtyn Beta, as a booster in adults aged 18 years and above. It is indicated as a booster in people of this age group who were earlier inoculated with a Covid-19 vaccine.

Vaccine 246

Vaccine Vaccination Immune Response Protein 246

Medical Xpress

MAY 16, 2023

Researchers at the University Medical Center Hamburg-Eppendorf have demonstrated cross-reactive immune responses to another SARS-CoV-2 protein besides the spike protein.

Protein 98

Protein Immune Response RNA Research 98

pharmaphorum

MARCH 15, 2021

MeMed CEO Dr. Eran Eden explores the relationship between the host immune response and SARS-CoV-2 infection and how technology could help personalise treatment strategies. This is made possible using ‘Advanced Host Immune Response Technologies’. The pace of work in the industry reached almost ludicrous speeds.

Immune Response 71

Immune Response Vaccine Vaccination Development 71

World of DTC Marketing

DECEMBER 29, 2020

Once introduced into the human body, the protein-making machinery uses this genetic material in our cells to churn out the coronavirus “spike protein,” triggering an immune response. While such platform technologies are a non-traditional approach, that does not mean they are untested.

Vaccine 307

Vaccine Vaccination Development Clinical Trials 307

Scienmag

MARCH 10, 2022

Close interactions with infectious disease set both University of California, Santa Cruz graduate student Ana Nuñez Castrejon and Associate Professor of Biomolecular Engineering Rebecca DuBois on the path of studying Respiratory syncytial virus (RSV), a common and sometimes dangerous respiratory disease for which there is not currently a vaccine.

Immune Response 77

Immune Response Vaccine Vaccination Protein 77

Scienmag

MARCH 17, 2022

The study, published in the journal Molecular Neurobiology led by the University’s Dr Mayo Olajide, describes how the spike protein used by the coronavirus to enter human cells can have a similar effect on the brain’s immune cells as it does with the rest of the body Credit: University of Huddersfield The study, published in […].

Immune Response 82

Immune Response Scientist Protein 82

Scienmag

NOVEMBER 16, 2021

Despite great progress with SARS-CoV-2 vaccines, there is still a need to accelerate vaccination in low- and middle-income countries and a need for more effective vaccine strategies in older adults, who tend to have weaker immune responses to vaccination.

Protein 84

Protein Vaccine Vaccination Immune Response 84

Pharmaceutical Technology

OCTOBER 25, 2022

A human monoclonal antibody, Imfinzi attaches to the PD-L1 protein and hinders the PD-L1 interaction with the PD-1 and CD80 proteins. Imjudo is also a human monoclonal antibody and hinders cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) activity.

Protein 173

Protein Immune Response Antibody FDA Approval 173

Medical Xpress

FEBRUARY 21, 2023

PCB2DG, a polyphenol with anti-inflammatory properties, works by targeting and directly interacting with the major glutamine transporter protein, alanine serine cysteine transporter 2 (ASCT2), to inhibit the uptake of glutamine, an important amino acid found in the blood.

Immune Response 74

Immune Response Regulation Protein 74

Scienmag

NOVEMBER 10, 2020

Mid-range level of immune protein associated with lowest risk Philadelphia, November 10, 2020 – The causes of autism spectrum disorder (ASD) – including genetic and environmental factors – are not entirely understood.

Immune Response 70

Immune Response Genetics Protein Medicine 70

Scienmag

MAY 26, 2021

A […].

Immune Response 54

Immune Response Protein Vaccine Vaccination 54

Pharmaceutical Technology

MARCH 31, 2023

Bimervax is a recombinant protein subunit vaccine, marketed by the Girona, Spain-based Hipra. Eligibility for the UK’s National Health Services (NHS) booster programmes in England is restricted to those ages 75 years and above or individuals with weakened immune systems.

Vaccine 277

Vaccine Vaccination Immune Response Antibody 277

BioPharma Reporter

DECEMBER 11, 2020

Sanofi and GSK announced a delay on Friday in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly, saying clinical trials showed an insufficient immune response in older people.

Immune Response 90

Immune Response Vaccine Vaccination Trials 90

pharmaphorum

JULY 6, 2021

While these types of tests are important, they don’t tell the whole story, as they can’t provide information on whether an individual has built an immune response to COVID-19, either through vaccination or through a previous infection. This is where antibody tests come in. The Importance of Antibody Certificates.

Antibody 111

Antibody Immune Response Protein Vaccine 111

Pharmaceutical Technology

FEBRUARY 15, 2023

Cancer monoclonal antibody therapy is a key innovation area in immuno-oncology Monoclonal antibodies are synthetic proteins that target cancer cells directly (targeted therapies) or help improve the immune system’s response to cancer cells (passive immunotherapy).

Antibody 261

Antibody Immune Response Protein Development 261

Medical Xpress

MAY 10, 2023

SLFN 12 shuts down viral protein production and helps virus-infected cells to escape from anti-HIV therapy and immune responses. These findings pave the way for improving therapeutic strategies that aim to cure HIV infections.

Immune Response 111

Immune Response Protein Production Research 111

Pharma Mirror

OCTOBER 16, 2023

The first mRNA drug (BNT162b2 vaccine) was granted emergency use authorization by the FDA in December 2020 and approved for marketing in August 2021.

Immune Response 130

Immune Response Drugs Protein Vaccine 130

XTalks

FEBRUARY 29, 2024

Dual-function fusion proteins represent a cutting-edge approach in biopharmaceutical research, offering a promising avenue for the development of novel therapeutics in the treatment of complex diseases such as cancer and autoimmune disorders. At the helm of this venture is Dr. Taylor H. How is your lead program differentiated?

Protein 94

Protein Development Clinical Trials Clinical Trials 94

Scienmag

OCTOBER 14, 2020

Treatment with a peptide that mimics the naturally occurring protein GIV prevents immune overreaction, supports a mechanism critical for survival in mouse models of sepsis and colitis Credit: UC San Diego Health Sciences The immune response to infections is a delicate balance.

Protein 67

Protein Immune Response Bacteria Allergies 67

XTalks

MAY 7, 2021

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 1.351 variant.

Protein 97

Protein Vaccine Vaccination Trials 97

pharmaphorum

JANUARY 5, 2022

A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial.

Protein 126

Protein Vaccine Vaccination Immune Response 126

Pharmaceutical Technology

MAY 29, 2023

A protein-based vaccine, Nuvaxovid has been recommended for MA for use as a primary series in individuals of the age 12 years and above and as a booster in those aged 18 years and older to prevent Covid-19. NVX-CoV2373 is developed by making copies of the surface spike protein of the SARS-CoV-2 virus that causes Covid.

Vaccine 130

Vaccine Vaccination Protein Immune Response 130

BioSpace

NOVEMBER 7, 2022

Researchers from the University of Washington have developed an investigational vaccine that can safely elicit an immune response against the HER2 protein, a key marker in breast cancer.

Immune Response 87

Immune Response Vaccine Vaccination Protein 87

Medical Xpress

FEBRUARY 14, 2023

This limits glucose availability for immune cells and therefore dampens the body's anti-cancer immune response. Tumor cells typically alter their energy metabolism and increase glucose uptake to support their rapid division and spread.

Immune Response 75

Immune Response Protein Scientist 75

The Pharma Data

MAY 17, 2021

The investigational COVID-19 vaccine uses the same recombinant protein-based technology as one of Sanofi’s seasonal flu vaccines, along with GSK’s established pandemic adjuvant technology. The interim results from the phase 2 trial on the vaccine, published today, on the contrary, showed a “ strong neutralizing antibody response” ?

Immune Response 52

Immune Response Vaccine Vaccination Antibody 52

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.

Immune Response 52

Immune Response Vaccine Vaccination Antibody 52

Pharmaceutical Technology

AUGUST 18, 2022

New Zealand’s Medsafe has granted expanded provisional approval for Novavax ’s protein-based Covid-19 vaccine Nuvaxovid (NVX-CoV2373) as a heterologous and homologous booster dose in adults aged 18 years and above. The booster vaccine is indicated for active immunisation for the prevention of Covid-19 in people of this age group.

Immune Response 130

Immune Response Vaccine Vaccination Protein 130

Medical Xpress

APRIL 17, 2023

The findings, published in Science Translational Medicine, suggests that breaches in damaged gums allow bacteria in the mouth to seep into the bloodstream, activating an immune response that ultimately pivots to target the body's own proteins and causes arthritis flareups.

Immune Response 98

Immune Response Bacteria Protein Medicine 98

Pharmaceutical Technology

APRIL 5, 2023

Initially, the company will use its reverse immunology technology to search the database for antibodies from patients showing strong immune responses. This is an important leap forward to better understand individualised protein-protein interactions on cancer cells, moving us toward delivering on the promise of personalised medicine.”

Development 130

Development Bioinformatics Drugs Immune Response 130

Camargo

JULY 27, 2021

As with any standard drug treatment, gene therapies carry potential risks, including adverse events, unexpected gene modification (activation or inactivation), undesired immune responses, or complications with the genetic material.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

Pharmaceutical Technology

NOVEMBER 20, 2022

Health Canada has granted expanded authorisation for Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted) [Nuvaxovid; NVX-CoV2373] as a homologous booster for usage in adults aged 18 and above. Novavax president and CEO Stanley Erck said: “Canadians now have access to our protein-based Nuvaxovid Covid-19 vaccine as an adult booster.

Vaccine 147

Vaccine Vaccination Immune Response Protein 147

pharmaphorum

JANUARY 12, 2021

For instance, oral vaccines could allow repeat dosing without a treatment-limiting anti-vector response – where the body generates an immune response against the harmless, non-replicating viruses used to deliver the COVID-19 antigens. There are other theoretical advantages as well.

Licensing 119

Licensing Licensing Vaccine Vaccination 119

Medical Xpress

DECEMBER 16, 2022

They have just discovered that a key immune alarm protein previously believed to calm down the immune response actually does the opposite. Scientists from Trinity College Dublin have made an important breakthrough in understanding how inflammation is regulated.

Immune Response 81

Immune Response Protein Scientist Regulation 81

Pharmaceutical Technology

JANUARY 19, 2023

Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain. The findings showed that the Nuvaxovid booster dose increased immune responses compared to higher levels associated with the protection in Phase III clinical trials.

Vaccine 147

Vaccine Vaccination Immune Response Protein 147

Scienmag

DECEMBER 9, 2021

When the body attempts to fight off an infection, immune cells called neutrophils may shoot out spider web-like networks of toxic proteins to help contain the invaders.

Immune Response 60

Immune Response Containment Protein Regulation 60

Scienmag

NOVEMBER 16, 2020

Cincinnati Children’s team reports controlling the BCAP protein could slow overactive immune response in IBD, rheumatoid arthritis or accelerate response against tumors Credit: Cincinnati Children’s Managing the activity of the BCAP protein could help the body repair intestinal tissue from damage caused by inflammation, according to a new (..)

Immune Response 78

Immune Response Protein Allergies Medicine 78

World of DTC Marketing

APRIL 11, 2021

Based on the virus a number of vaccines targeting the spike protein were designed, tested in animal models and found to be quite promising against SARS and other coronavirus illnesses like Middle East respiratory syndrome. However, the continued study of the virus was shelved because of the lack of funding.

Vaccine 303

Vaccine Vaccination Clinical Trials Clinical Trials 303